---
figid: PMC4919572__gr8
figlink: /pmc/articles/PMC4919572/figure/f0040/
number: F8
caption: 'Signaling model at a glance. In cells with FL p62 DOK1 at the membrane or
  cytoplasmic p44 DC mutant, oncogenic signaling of many target proteins is inhibited
  (such as RTK, CTK, SMAD, RAS, ELK1 e.a.) leading to reduction of SRE transcription
  (which drives cells into G1-S phase) and activation of PPRE transcription (which
  dampens cell proliferation), two exemplary read-outs used in the present study.
  PPARγ-agonist (star) further augments PPARγ-mediated growth inhibition, resulting
  in a good prognosis for patients'' survival. Mechanistically, DOK1 may act as a
  “co-chaperone” for ligand-dependent nuclear translocation of PPARγ across the ER
  and nuclear pores. In tumor cells with loss of FL p62 DOK1 or accumulation of nuclear
  p33 DN mutant, oncogenic signaling (depicted here exemplary for the RAS-ERK1/2-ELK1-SRF
  pathway) is unimpeded leading to enhanced SRE and reduced PPRE transcription, resulting
  in tumor cell proliferation and a poor prognosis. Mechanistically, MEK1 and ERK1/2
  inhibit nuclear translocation of PPARγ by promoting its export to the cytoplasm
  and inactivation by phosphorylation. Legend: red = active oncogene; blue black = active
  tumor suppressor; grey = inactive protein.'
pmcid: PMC4919572
papertitle: Subcellular compartmentalization of docking protein-1 contributes to progression
  in colorectal cancer.
reftext: Teresa Friedrich, et al. EBioMedicine. 2016 Jun;8:159-172.
pmc_ranked_result_index: '64215'
pathway_score: 0.8770918
filename: gr8.jpg
figtitle: Signaling model at a glance
year: '2016'
organisms:
- Homo sapiens
ndex: 4483328d-df14-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4919572__gr8.html
  '@type': Dataset
  description: 'Signaling model at a glance. In cells with FL p62 DOK1 at the membrane
    or cytoplasmic p44 DC mutant, oncogenic signaling of many target proteins is inhibited
    (such as RTK, CTK, SMAD, RAS, ELK1 e.a.) leading to reduction of SRE transcription
    (which drives cells into G1-S phase) and activation of PPRE transcription (which
    dampens cell proliferation), two exemplary read-outs used in the present study.
    PPARγ-agonist (star) further augments PPARγ-mediated growth inhibition, resulting
    in a good prognosis for patients'' survival. Mechanistically, DOK1 may act as
    a “co-chaperone” for ligand-dependent nuclear translocation of PPARγ across the
    ER and nuclear pores. In tumor cells with loss of FL p62 DOK1 or accumulation
    of nuclear p33 DN mutant, oncogenic signaling (depicted here exemplary for the
    RAS-ERK1/2-ELK1-SRF pathway) is unimpeded leading to enhanced SRE and reduced
    PPRE transcription, resulting in tumor cell proliferation and a poor prognosis.
    Mechanistically, MEK1 and ERK1/2 inhibit nuclear translocation of PPARγ by promoting
    its export to the cytoplasm and inactivation by phosphorylation. Legend: red = active
    oncogene; blue black = active tumor suppressor; grey = inactive protein.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PPARA
  - PPARD
  - MAP2K2
  - SMAD6
  - PPARG
  - ARAF
  - MAP2K1
  - SMAD5
  - SMAD9
  - SMAD7
  - SMAD3
  - SMAD4
  - SRF
  - MAPK3
  - RAF1
  - SMAD2
  - BRAF
  - MAPK1
  - MATK
  - SMAD1
  - NRAS
  - DOK1
  - HRAS
  - KRAS
  - Cancer
  - Cardiomyopathy
  - Noonan syndrome
genes:
- word: PPAR
  symbol: PPAR
  source: bioentities_symbol
  hgnc_symbol: PPARA
  entrez: '5465'
- word: PPAR
  symbol: PPAR
  source: bioentities_symbol
  hgnc_symbol: PPARD
  entrez: '5467'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K2
  entrez: '5605'
- word: SMAD
  symbol: SMAD
  source: bioentities_symbol
  hgnc_symbol: SMAD6
  entrez: '4091'
- word: PPAR
  symbol: PPAR
  source: bioentities_symbol
  hgnc_symbol: PPARG
  entrez: '5468'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: ARAF
  entrez: '369'
- word: MEK
  symbol: MEK
  source: bioentities_symbol
  hgnc_symbol: MAP2K1
  entrez: '5604'
- word: SMAD
  symbol: SMAD
  source: bioentities_symbol
  hgnc_symbol: SMAD5
  entrez: '4090'
- word: SMAD
  symbol: SMAD
  source: bioentities_symbol
  hgnc_symbol: SMAD9
  entrez: '4093'
- word: SMAD
  symbol: SMAD
  source: bioentities_symbol
  hgnc_symbol: SMAD7
  entrez: '4092'
- word: SMAD
  symbol: SMAD
  source: bioentities_symbol
  hgnc_symbol: SMAD3
  entrez: '4088'
- word: SMAD
  symbol: SMAD
  source: bioentities_symbol
  hgnc_symbol: SMAD4
  entrez: '4089'
- word: SRF
  symbol: SRF
  source: hgnc_symbol
  hgnc_symbol: SRF
  entrez: '6722'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: RAF1
  entrez: '5894'
- word: SMAD
  symbol: SMAD
  source: bioentities_symbol
  hgnc_symbol: SMAD2
  entrez: '4087'
- word: RAF
  symbol: RAF
  source: bioentities_symbol
  hgnc_symbol: BRAF
  entrez: '673'
- word: ERK
  symbol: ERK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: CTK
  symbol: CTK
  source: hgnc_alias_symbol
  hgnc_symbol: MATK
  entrez: '4145'
- word: SMAD
  symbol: SMAD
  source: bioentities_symbol
  hgnc_symbol: SMAD1
  entrez: '4086'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: NRAS
  entrez: '4893'
- word: 'DOK1:'
  symbol: DOK1
  source: hgnc_symbol
  hgnc_symbol: DOK1
  entrez: '1796'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: HRAS
  entrez: '3265'
- word: RAS
  symbol: RAS
  source: bioentities_symbol
  hgnc_symbol: KRAS
  entrez: '3845'
chemicals: []
diseases:
- word: Cancer
  source: ''
  identifier: ''
- word: Cardiomyopathy
  source: ''
  identifier: ''
- word: Noonan syndrome
  source: ''
  identifier: ''
figid_alias: PMC4919572__F8
redirect_from: /figures/PMC4919572__F8
figtype: Figure
---
